Genmab

Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

First Quarter 2013 Financial Results

Genmab reported its First Quarter 2013 financial results after market close on May 7. Click here to listen to the webcast. Click here to download slides.

Updated Daratumumab Data Presented at International Myeloma Workshop

Updated data from the Phase I/II study of daratumumab in refractory multiple myeloma was presented at the 14th International Myeloma Workshop in Kyoto, Japan on April 4.  Click here to view the poster.

New DuoBody.com Website Launched

Genmab has launched a new website dedicated to its DuoBody® technology platform. Visit the new site at www.DuoBody.com. We have also recently published key scientific research on DuoBody, Click here to read the article.